Evidence Table MULTI.2. Continuous outcomes of MULTI-ARM trials

Trial Continuous Outcome Name (Units)

Comments re Between P-value

Follow 

up

Between 

P-value

Treatment

Data Type: Mean (SD) SS Within P

53 Comedones change (%)

P Mod/sev Percent change: -28 44

Í Short (6) Benzoyl peroxide NS

53 Comedones change (%)

P Mod/sev Percent change: -28 44

Í Benzoyl peroxide "Sig"

Vs Placebo

Mid (10)

53 Comedones change (%)

P Mod/sev Percent change: -12 45

Í Short (6) Erythromycin NS

53 Comedones change (%)

P Mod/sev Percent change: -18 45

Í Erythromycin "Sig"

Vs Placebo

Mid (10)

53 Comedones change (%)

P Mod/sev Percent change: -28 44

Í Short (6) Erythromycin + benzoyl peroxide NS

53 Comedones change (%)

P Mod/sev Percent change: -28 44

Í Erythromycin + benzoyl peroxide "Sig"

Vs Placebo

Mid (10)

53 Comedones change (%)

P Mod/sev Percent change: -12 44

Í Short (6) Vehicle NS

53 Comedones change (%)

P Mod/sev Percent change: -2 44

Í Mid (10) Vehicle NS

53 Inflammatory change (%)

P Mod/sev Percent change: -42 44

Í Benzoyl peroxide "Sig"

Vs Placebo; BP = E

Short (6)

53 Inflammatory change (%)

P Mod/sev Percent change: -58 44

Í Benzoyl peroxide "Sig"

Vs Placebo; BP = E

Mid (10)

53 Inflammatory change (%)

P Mod/sev Percent change: -42 45

Í Erythromycin "Sig"

Vs Placebo; E = BP

Short (6)

53 Inflammatory change (%)

P Mod/sev Percent change: -60 45

Í Erythromycin "Sig"

Vs Placebo; E = BP

Mid (10)

53 Inflammatory change (%)

P Mod/sev Percent change: -62 44

Í Erythromycin + benzoyl peroxide "Sig"

Vs BP, E, Placebo

Short (6)

53 Inflammatory change (%)

P Mod/sev Percent change: -78 44

Í Erythromycin + benzoyl peroxide "Sig"

Vs BP, E, Placebo

Mid (10)

53 Inflammatory change (%)

P Mod/sev Percent change: -15 44

Í Short (6) Vehicle NS

53 Inflammatory change (%)

P Mod/sev Percent change: -28 44

Í Mid (10) Vehicle NS

53 Papules change (%)

P Mod/sev Percent change: -38 44

Í Benzoyl peroxide "Sig"

Vs Placebo; BP = E

Short (6)

53 Papules change (%)

P Mod/sev Percent change: -54 44

Í Benzoyl peroxide "Sig"

Vs Placebo; BP = E

Mid (10)

53 Papules change (%)

P Mod/sev Percent change: -40 45

Í Erythromycin "Sig"

Vs Placebo; E = BP

Short (6)

 TRIAL: refer to the presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., refer to our assessment of entry severity of 

study patients. "P" refers to parallel study, "S," to split face design. TREATMENT: "Percent change" indicates an outcome derived from individual final and baseline 

measures; "Percent change*" indicates that we calculated a group-based percentage change; "Change" indicates raw difference from baseline; "Change*" indicates 

calculated change; "Measure" indicates an outcome measure with no baseline comparison. SD indicates standard deviation, SS, sample size (with * means calcuted as total 

sample size divided by number of arms), and WITHIN P, P-value with respect to baseline."M" means no P-value available. BETWEENP-VALUE: a comparison between 

Treatment and another treatment. "Sig" indicates authors' statement regarding statistical significance, without quantitation.

Table MULTI.2 Page 1 of 10

ÈÍ
Trial Continuous Outcome Name (Units)

Comments re Between P-value

Follow 

up

Between 

P-value

Treatment

Data Type: Mean (SD) SS Within P

53 Papules change (%)

P Mod/sev Percent change: -50 45

Í Erythromycin "Sig"

Vs Placebo; E = BP

Mid (10)

53 Papules change (%)

P Mod/sev Percent change: -58 44

Í Erythromycin + benzoyl peroxide "Sig"

Vs E

Short (6)

53 Papules change (%)

P Mod/sev Percent change: -70 44

Í Erythromycin + benzoyl peroxide "Sig"

Vs E

Mid (10)

53 Papules change (%)

P Mod/sev Percent change: -15 44

Í Short (6) Vehicle NS

53 Papules change (%)

P Mod/sev Percent change: -30 44

Í Mid (10) Vehicle NS

53 Pustules change (%)

P Mod/sev Percent change: -55 44

Í Benzoyl peroxide "Sig"

Vs Placebo; BP = E = E + BP

Short (6)

53 Pustules change (%)

P Mod/sev Percent change: -70 44

Í Benzoyl peroxide "Sig"

Vs Placebo

Mid (10)

53 Pustules change (%)

P Mod/sev Percent change: -48 45

Í Erythromycin "Sig"

Vs Placebo; E = BP = E + BP

Short (6)

53 Pustules change (%)

P Mod/sev Percent change: -70 45

Í Erythromycin "Sig"

Vs Placebo

Mid (10)

53 Pustules change (%)

P Mod/sev Percent change: -80 44

Í Erythromycin + benzoyl peroxide "Sig"

Vs Placebo; E + BP = BP = E

Short (6)

53 Pustules change (%)

P Mod/sev Percent change: -90 44

Í Erythromycin + benzoyl peroxide "Sig"

Vs Placebo

Mid (10)

53 Pustules change (%)

P Mod/sev Percent change: -10 44

Í Short (6) Vehicle NS

53 Pustules change (%)

P Mod/sev Percent change: -28 44

Í Mid (10) Vehicle NS

97 Total lesions change (%)

P Mild/mod Percent change: -37 48 M

È Benzoyl peroxide 0.001

With respect to placebo

Short (4)

97 Total lesions change (%)

P Mild/mod Percent change: -56 54 M

È Benzoyl peroxide + chlorhydroxyquinoline NS

With respect to placebo

Short (4)

97 Total lesions change (%)

P Mild/mod Percent change: 6 48 M

È Vehicle 0.001

With respect to placebo

Short (4)

108 Medication used (mg/kg)

P Raw measure: 27 39

Mild/mod/se

v

Mid (10) Erythromycin + zinc (gel) + Placebo (oral)

 TRIAL: refer to the presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., refer to our assessment of entry severity of 

study patients. "P" refers to parallel study, "S," to split face design. TREATMENT: "Percent change" indicates an outcome derived from individual final and baseline 

measures; "Percent change*" indicates that we calculated a group-based percentage change; "Change" indicates raw difference from baseline; "Change*" indicates 

calculated change; "Measure" indicates an outcome measure with no baseline comparison. SD indicates standard deviation, SS, sample size (with * means calcuted as total 

sample size divided by number of arms), and WITHIN P, P-value with respect to baseline."M" means no P-value available. BETWEENP-VALUE: a comparison between 

Treatment and another treatment. "Sig" indicates authors' statement regarding statistical significance, without quantitation.

Table MULTI.2 Page 2 of 10

ÈÍ
Trial Continuous Outcome Name (Units)

Comments re Between P-value

Follow 

up

Between 

P-value

Treatment

Data Type: Mean (SD) SS Within P

108 Medication used (mg/kg)

P Raw measure: 86 40

Mild/mod/se

v

Erythromycin + zinc (liquid) + placebo 

(oral)

Mid (10)

108 Medication used (mg/kg)

P Raw measure: 463 39

Mild/mod/se

v

Mid (10) Tetracycline (oral) + placebo (topical)

108 Papules change (%)

P Percent change: -39 (50.) 39

Mild/mod/se

v

Erythromycin + zinc (gel) + Placebo (oral) 0.05

Gel = tet liq > pl

Short (6)

108 Papules change (%)

P Percent change: -45 (50.) 39

Mild/mod/se

v

Erythromycin + zinc (gel) + Placebo (oral) 0.05

EZ liquid, gel = Tet

Mid (10)

108 Papules change (%)

P Percent change: -52 (50.) 40

Mild/mod/se

v

Erythromycin + zinc (liquid) + placebo 0.001

(oral)

Gel = tet liq > pl

Short (6)

108 Papules change (%)

P Percent change: -58 (50.) 40

Mild/mod/se

v

Erythromycin + zinc (liquid) + placebo 0.001

(oral)

EZ liquid, gel = Tet

Mid (10)

108 Papules change (%)

P Percent change: -23 (50.) 31

Mild/mod/se

v

Placebo (topical) + placebo (oral)

Gel = tet liq > pl

Short (6)

108 Papules change (%)

P Percent change: -25 (50.) 31

Mild/mod/se

v

Placebo (topical) + placebo (oral) NS

EZ liquid, gel = Tet

Mid (10)

108 Papules change (%)

P Percent change: -55 (50.) 39

Mild/mod/se

v

Tetracycline (oral) + placebo (topical)

Gel = tet liq > pl

Short (6)

108 Papules change (%)

P Percent change: -51 (50.) 39

Mild/mod/se

v

Tetracycline (oral) + placebo (topical) 0.01

EZ liquid, gel = Tet

Mid (10)

 TRIAL: refer to the presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., refer to our assessment of entry severity of 

study patients. "P" refers to parallel study, "S," to split face design. TREATMENT: "Percent change" indicates an outcome derived from individual final and baseline 

measures; "Percent change*" indicates that we calculated a group-based percentage change; "Change" indicates raw difference from baseline; "Change*" indicates 

calculated change; "Measure" indicates an outcome measure with no baseline comparison. SD indicates standard deviation, SS, sample size (with * means calcuted as total 

sample size divided by number of arms), and WITHIN P, P-value with respect to baseline."M" means no P-value available. BETWEENP-VALUE: a comparison between 

Treatment and another treatment. "Sig" indicates authors' statement regarding statistical significance, without quantitation.

Table MULTI.2 Page 3 of 10

ÈÍ
Trial Continuous Outcome Name (Units)

Comments re Between P-value

Follow 

up

Between 

P-value

Treatment

Data Type: Mean (SD) SS Within P

108 Severity change (Cook)

P Raw measure: -33 (50.) 39

Mild/mod/se

v

Short (6) Erythromycin + zinc (gel) + Placebo (oral) 0.01

108 Severity change (Cook)

P Raw measure: -39 (50.) 40

Mild/mod/se

v

Erythromycin + zinc (liquid) + placebo 0.001

(oral)

Short (6)

108 Severity change (Cook)

P Raw measure: 14 (50.) 31

Mild/mod/se

v

Short (6) Placebo (topical) + placebo (oral) NS

108 Severity change (Cook)

P Raw measure: -35 (50.) 39

Mild/mod/se

v

Short (6) Tetracycline (oral) + placebo (topical) 0.01

108 Severity change (Cook %)

P Raw measure: -33 (50.) 39

Mild/mod/se

v

Mid (10) Erythromycin + zinc (gel) + Placebo (oral) 0.01

108 Severity change (Cook %)

P Raw measure: -46 (50.) 40

Mild/mod/se

v

Erythromycin + zinc (liquid) + placebo 0.001

(oral)

Mid (10)

108 Severity change (Cook %)

P Raw measure: -7 (50.) 31

Mild/mod/se

v

Mid (10) Placebo (topical) + placebo (oral)

108 Severity change (Cook %)

P Raw measure: -32 (50.) 39

Mild/mod/se

v

Mid (10) Tetracycline (oral) + placebo (topical) 0.01

109 Total lesions (count)

P Mod Change*: -8 *21 0.0001

Í Mid (12) Benzoyl peroxide (contingent contract) 0.04

109 Total lesions (count)

P Mod Change*: -13 *21 0.0001

Í Mid (12) Benzoyl peroxide (non-contingent contract) 0.04

109 Total lesions (count)

P Mod Change*: -15 *21 0.0001

Í Mid (12) Benzoyl peroxide (self monitoring) 0.04

109 Total lesions (count)

P Mod Change*: 0 *21 M

Í Mid (12) Untreated NS

 TRIAL: refer to the presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., refer to our assessment of entry severity of 

study patients. "P" refers to parallel study, "S," to split face design. TREATMENT: "Percent change" indicates an outcome derived from individual final and baseline 

measures; "Percent change*" indicates that we calculated a group-based percentage change; "Change" indicates raw difference from baseline; "Change*" indicates 

calculated change; "Measure" indicates an outcome measure with no baseline comparison. SD indicates standard deviation, SS, sample size (with * means calcuted as total 

sample size divided by number of arms), and WITHIN P, P-value with respect to baseline."M" means no P-value available. BETWEENP-VALUE: a comparison between 

Treatment and another treatment. "Sig" indicates authors' statement regarding statistical significance, without quantitation.

Table MULTI.2 Page 4 of 10

ÈÍ
Trial Continuous Outcome Name (Units)

Comments re Between P-value

Follow 

up

Between 

P-value

Treatment

Data Type: Mean (SD) SS Within P

119 Irritation (score)

P s Raw measure: 0 28 M

È Short (3) Adapalene M

119 Irritation (score)

P s Raw measure: 0 (0.38) 28 M

È Short (3) Adapalene M

119 Irritation (score)

P s Raw measure: 0 (0.31) 28 M

È Short (3) Petrolatum M

119 Irritation (score)

P s Raw measure: 0 28 M

È Short (3) Petrolatum M

119 Irritation (score)

P s Raw measure: 2 (0.37) 28 M

È Short (3) Tretinoin (0.01% gel) M

119 Irritation (score)

P s Raw measure: 3 28 M

È Short (3) Tretinoin (0.01% gel) M

119 Irritation (score)

P s Raw measure: 2 28 M

È Short (3) Tretinoin (0.025% cream) M

119 Irritation (score)

P s Raw measure: 2 (0.37) 28 M

È Short (3) Tretinoin (0.025% cream) M

119 Irritation (score)

P s Raw measure: 3 28 M

È Short (3) Tretinoin (0.025% gel) M

119 Irritation (score)

P s Raw measure: 2 (0.42) 28 M

È Short (3) Tretinoin (0.025% gel) M

119 Irritation (score)

P s Raw measure: 2 (0.29) 28 M

È Short (3) Tretinoin (0.05% cream) M

119 Irritation (score)

P s Raw measure: 3 28 M

È Short (3) Tretinoin (0.05% cream) M

119 Irritation (score)

P s Raw measure: 2 (0.34) 28 M

È Short (3) Tretinoin (0.1% cream) M

119 Irritation (score)

P s Raw measure: 3 28 M

È Short (3) Tretinoin (0.1% cream) M

120 Irritation (score)

P s Raw measure: 0 27 M

È Short (3) Adapalene M

120 Irritation (score)

P s Raw measure: 0 27 M

È Short (3) Petrolatum M

120 Irritation (score)

P s Raw measure: 2 27 M

È Short (3) Tretinoin (0 .1% cream) M

120 Irritation (score)

P s Raw measure: 2 27 M

È Short (3) Tretinoin (0.025% cream) M

120 Irritation (score)

P s Raw measure: 2 27 M

È Short (3) Tretinoin (0.05% cream) M

 TRIAL: refer to the presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., refer to our assessment of entry severity of 

study patients. "P" refers to parallel study, "S," to split face design. TREATMENT: "Percent change" indicates an outcome derived from individual final and baseline 

measures; "Percent change*" indicates that we calculated a group-based percentage change; "Change" indicates raw difference from baseline; "Change*" indicates 

calculated change; "Measure" indicates an outcome measure with no baseline comparison. SD indicates standard deviation, SS, sample size (with * means calcuted as total 

sample size divided by number of arms), and WITHIN P, P-value with respect to baseline."M" means no P-value available. BETWEENP-VALUE: a comparison between 

Treatment and another treatment. "Sig" indicates authors' statement regarding statistical significance, without quantitation.

Table MULTI.2 Page 5 of 10

ÈÍ
Trial Continuous Outcome Name (Units)

Comments re Between P-value

Follow 

up

Between 

P-value

Treatment

Data Type: Mean (SD) SS Within P

120 Irritation (score)

P s Raw measure: 2 27 M

È Short (3) Tretinoin (0.1% gel) M

120 Local reactions/Irritation (Cumulative 

score) Raw measure: 0 27 M

P s 

È Short (3) Adapalene M

120 Local reactions/Irritation (Cumulative 

score) Raw measure: 0 27 M

P s 

È Short (3) Petrolatum M

120 Local reactions/Irritation (Cumulative 

score) Raw measure: 2 27 M

P s 

È Short (3) Tretinoin (0 .1% cream) M

120 Local reactions/Irritation (Cumulative 

score) Raw measure: 1 27 M

P s 

È Short (3) Tretinoin (0.025% cream) M

120 Local reactions/Irritation (Cumulative 

score) Raw measure: 1 27 M

P s 

È Short (3) Tretinoin (0.05% cream) M

120 Local reactions/Irritation (Cumulative 

score) Raw measure: 1 27 M

P s 

È Short (3) Tretinoin (0.1% gel) M

149 Time to favorable status (mean weeks)

P Raw measure: 7 50

Mild/mod/se

v

Í Mid (10) Benzoyl peroxide (5%) NS

149 Time to favorable status (mean weeks)

P Raw measure: 6 50

Mild/mod/se

v

Í Mid (10) Benzoyl peroxide (10%) NS

149 Time to favorable status (mean weeks)

P Raw measure: 7 50

Mild/mod/se

v

Í Mid (10) Tretinoin NS

156 Severity (Michaelsson)

P Mod/sev Raw measure: 60 (18.) 9 0.01

Í Mid (12) Cimetidine [men] M

156 Severity (Michaelsson)

P Mod/sev Raw measure: 44 (29.) 16 0.001

Í Mid (12) Cimetidine [women] M

156 Severity (Michaelsson)

P Mod/sev Raw measure: 48 (30.) 10 M

Í Mid (12) Spironolactone [men] M

156 Severity (Michaelsson)

P Mod/sev Raw measure: 32 (22.4) 15 M

Í Mid (12) Spironolactone [women] M

 TRIAL: refer to the presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., refer to our assessment of entry severity of 

study patients. "P" refers to parallel study, "S," to split face design. TREATMENT: "Percent change" indicates an outcome derived from individual final and baseline 

measures; "Percent change*" indicates that we calculated a group-based percentage change; "Change" indicates raw difference from baseline; "Change*" indicates 

calculated change; "Measure" indicates an outcome measure with no baseline comparison. SD indicates standard deviation, SS, sample size (with * means calcuted as total 

sample size divided by number of arms), and WITHIN P, P-value with respect to baseline."M" means no P-value available. BETWEENP-VALUE: a comparison between 

Treatment and another treatment. "Sig" indicates authors' statement regarding statistical significance, without quantitation.

Table MULTI.2 Page 6 of 10

ÈÍ
Trial Continuous Outcome Name (Units)

Comments re Between P-value

Follow 

up

Between 

P-value

Treatment

Data Type: Mean (SD) SS Within P

177 Face severity (Jaffe)

P Raw measure: -3 (0.12) 28 0.001

È Mid (12) Benzoyl peroxide M

177 Face severity (Jaffe)

P Raw measure: -5 (0.17) 25 0.0001

È Mid (12) Hydroxyquinoline + benzoyl peroxide M

177 Face severity (Jaffe)

P Raw measure: -3 (0.1) 27 0.001

È Mid (12) Vehicle M

214 Inflammatory change (%)

P Mod Percent change: -39 (4.) 92 M

È Mid (11) Benzoyl peroxide 0.02

214 Inflammatory change (%)

P Mod Percent change: -35 (5.) 89 M

È Mid (11) Clindamycin 0.02

214 Inflammatory change (%)

P Mod Percent change: -61 (3.) 95 M

È Mid (11) Clindamycin + benzoyl peroxide 0.02

214 Inflammatory change (%)

P Mod Percent change: 5 (7.) 58 M

È Mid (11) Vehicle NS

214 Non-inflammatory change (%)

P Mod Percent change: -30 (4.) 92 M

È Mid (11) Benzoyl peroxide 0.005

214 Non-inflammatory change (%)

P Mod Percent change: -9 (6.) 89 M

È Clindamycin 0.04

.01 vs clinda alone

Mid (11)

214 Non-inflammatory change (%)

P Mod Percent change: -36 (4.) 95 M

È Clindamycin + benzoyl peroxide 0.004

.01 vs clinda alone

Mid (11)

214 Non-inflammatory change (%)

P Mod Percent change: -11 (8.) 58 M

È Mid (11) Vehicle NS

229 Inflammatory change (%)

P s Mod/sev Percent change: -51 (34.) 23 M

È Short (4) Clindamycin hydrochloride (E-solve®) NS

229 Inflammatory change (%)

P s Mod/sev Percent change: -75 (22.) 23 M

È Clindamycin hydrochloride (E-solve®) 0.001

Vs.clindamycin hydrochloride(Ionax®)

Mid (8)

229 Inflammatory change (%)

P s Mod/sev Percent change: -70 (18.) 16 M

È Short (4) Clindamycin hydrochloride (Ionax®) NS

229 Inflammatory change (%)

P s Mod/sev Percent change: -83 (19.) 16 M

È Clindamycin hydrochloride (Ionax®) 0.001

Vs.clindamycin hydrochloride(E-solve®)

Mid (8)

229 Inflammatory change (%)

P s Mod/sev Percent change: 65 (32.) 16 M

È Short (4) Clindamycin phosphate (E-solve®) NS

229 Inflammatory change (%)

P s Mod/sev Percent change: -83 (22.) 17 M

È Clindamycin phosphate (E-solve®) NS

Vs.clindamycin phosphate(Ionax®)

Mid (8)

229 Inflammatory change (%)

P s Mod/sev Percent change: -66 (18.) 21 M

È Short (4) Clindamycin phosphate (Ionax®) NS

229 Inflammatory change (%)

P s Mod/sev Percent change: -81 (16.) 20 M

È Clindamycin phosphate (Ionax®) NS

Vs. Clindamycin phosphate (e-solve)

Mid (8)

 TRIAL: refer to the presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., refer to our assessment of entry severity of 

study patients. "P" refers to parallel study, "S," to split face design. TREATMENT: "Percent change" indicates an outcome derived from individual final and baseline 

measures; "Percent change*" indicates that we calculated a group-based percentage change; "Change" indicates raw difference from baseline; "Change*" indicates 

calculated change; "Measure" indicates an outcome measure with no baseline comparison. SD indicates standard deviation, SS, sample size (with * means calcuted as total 

sample size divided by number of arms), and WITHIN P, P-value with respect to baseline."M" means no P-value available. BETWEENP-VALUE: a comparison between 

Treatment and another treatment. "Sig" indicates authors' statement regarding statistical significance, without quantitation.

Table MULTI.2 Page 7 of 10

ÈÍ
Trial Continuous Outcome Name (Units)

Comments re Between P-value

Follow 

up

Between 

P-value

Treatment

Data Type: Mean (SD) SS Within P

229 Inflammatory change (%)

P s Mod/sev Percent change: -55 (37.) 17 M

È Short (4) E-solve® NS

229 Inflammatory change (%)

P s Mod/sev Percent change: -78 (19.) 19 M

È E-solve® NS

Vs. Ionax®

Mid (8)

229 Inflammatory change (%)

P s Mod/sev Percent change: -63 (28.) 23 M

È Short (4) Ionax® NS

229 Inflammatory change (%)

P s Mod/sev Percent change: -76 (18.) 23 M

È Ionax® NS

Vs. E-solve®

Mid (8)

233 Severity change (Michaelsson %)

P Mod/sev Raw measure: -25 (30.) 14 M

È Short (4) Vehicle NS

233 Severity change (Michaelsson %)

P Mod/sev Raw measure: -30 (27.) 14 M

È Short (4) Vitamin A palmitate NS

233 Severity change (Michaelsson %)

P Mod/sev Raw measure: -64 (15.) 15 M

È Short (4) Zinc sulfate NS

233 Severity change (Michaelsson %)

P Mod/sev Raw measure: -58 (15.) 18 M

È Short (4) Zinc sulfate + Vitamin A palmitate NS

239 Non-inflammatory change (%)

P Mod/sev Percent change: -19 10

Í Mid (8) Aluminum oxide NS

266 Inflammatory (count)

P Mod Change*: -4 15 NS

È Short (6) Placebo

266 Inflammatory (count)

P Mod Change*: -7 14 NS

È Short (6) Shankhabhasma vah

266 Inflammatory (count)

P Mod Change*: -4 16 NS

È Short (6) Sookshama triphala

266 Inflammatory (count)

P Mod Change*: -14 20 0.01

È Short (6) Sunder vati

266 Inflammatory (count)

P Mod Change*: -4 17 NS

È Short (6) Thiostanin

266 Non-inflammatory (count)

P Mod Raw count: 46 (2.8) 15 NS

È Short (6) Placebo

266 Non-inflammatory (count)

P Mod Raw count: 46 (2.8) 14 NS

È Short (6) Shankhabhasma vah

266 Non-inflammatory (count)

P Mod Raw count: 46 (2.) 16 NS

È Short (6) Sookshama triphala

266 Non-inflammatory (count)

P Mod Raw count: 35 (4.) 20 0.01

È Short (6) Sunder vati

 TRIAL: refer to the presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., refer to our assessment of entry severity of 

study patients. "P" refers to parallel study, "S," to split face design. TREATMENT: "Percent change" indicates an outcome derived from individual final and baseline 

measures; "Percent change*" indicates that we calculated a group-based percentage change; "Change" indicates raw difference from baseline; "Change*" indicates 

calculated change; "Measure" indicates an outcome measure with no baseline comparison. SD indicates standard deviation, SS, sample size (with * means calcuted as total 

sample size divided by number of arms), and WITHIN P, P-value with respect to baseline."M" means no P-value available. BETWEENP-VALUE: a comparison between 

Treatment and another treatment. "Sig" indicates authors' statement regarding statistical significance, without quantitation.

Table MULTI.2 Page 8 of 10

ÈÍ
Trial Continuous Outcome Name (Units)

Comments re Between P-value

Follow 

up

Between 

P-value

Treatment

Data Type: Mean (SD) SS Within P

266 Non-inflammatory (count)

P Mod Raw count: 45 (4.) 17 NS

È Short (6) Thiostanin

302 Burning

P s Mild Raw measure: 1 20

Í Mid (10) Tretinoin (0.01%) NS

302 Burning

P s Mild Raw measure: 2 10

Í Mid (10) Tretinoin (0.025%) NS

302 Burning

P s Mild Raw measure: 2 10

Í Mid (10) Tretinoin (0.05%) NS

302 Erythema

P s Mild Raw measure: 1 20

Í Tretinoin (0.01%)

Only significant compared to patients 

asses .025%

Mid (10)

302 Erythema

P s Mild Raw measure: 2 10

Í Mid (10) Tretinoin (0.025%) NS

302 Erythema

P s Mild Raw measure: 1 10

Í Mid (10) Tretinoin (0.05%) NS

302 Scaling

P s Mild Raw measure: 1 20

Í Mid (10) Tretinoin (0.01%)

302 Scaling

P s Mild Raw measure: 2 10 M

Í Tretinoin (0.025%) 0.05

Only significant in does assess with 

respect to .025

Mid (10)

302 Scaling

P s Mild Raw measure: 2 10

Í Mid (10) Tretinoin (0.05%) NS

302 Comedones (count)

P s Mild Change*: -7 20 M

Í Mid (10) Tretinoin (0.01%) M

302 Comedones (count)

P s Mild Change*: -7 20

Í Mid (10) Tretinoin combined NS

302 Inflammatory (count)

P s Mild Change*: -4 20

Í Mid (10) Tretinoin (0.01%) 0.05

302 Inflammatory (count)

P s Mild Change*: -7 20 M

Í Mid (10) Tretinoin combined M

302 Comedones (improvement)

P s Mild Raw measure: 13 20

Í Short (6) Tretinoin (0.01%) 0.05

302 Comedones (improvement)

P s Mild Raw measure: 14 20 M

Í Mid (10) Tretinoin (0.01%) M

302 Comedones (improvement)

P s Mild Raw measure: 10 20

Í Short (6) Tretinoin combined 0.05

302 Comedones (improvement)

P s Mild Raw measure: 12 20 M

Í Mid (10) Tretinoin combined M

 TRIAL: refer to the presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., refer to our assessment of entry severity of 

study patients. "P" refers to parallel study, "S," to split face design. TREATMENT: "Percent change" indicates an outcome derived from individual final and baseline 

measures; "Percent change*" indicates that we calculated a group-based percentage change; "Change" indicates raw difference from baseline; "Change*" indicates 

calculated change; "Measure" indicates an outcome measure with no baseline comparison. SD indicates standard deviation, SS, sample size (with * means calcuted as total 

sample size divided by number of arms), and WITHIN P, P-value with respect to baseline."M" means no P-value available. BETWEENP-VALUE: a comparison between 

Treatment and another treatment. "Sig" indicates authors' statement regarding statistical significance, without quantitation.

Table MULTI.2 Page 9 of 10

ÈÍ
Trial Continuous Outcome Name (Units)

Comments re Between P-value

Follow 

up

Between 

P-value

Treatment

Data Type: Mean (SD) SS Within P

302 Inflammatory (improvement)

P s Mild Raw measure: 13 20 M

Í Short (6) Tretinoin (0.01%) M

302 Inflammatory (improvement)

P s Mild Raw measure: 14 20

Í Mid (10) Tretinoin (0.01%) 0.05

302 Inflammatory (improvement)

P s Mild Raw measure: 12 20 M

Í Short (6) Tretinoin combined M

302 Inflammatory (improvement)

P s Mild Raw measure: 13 20

Í Mid (10) Tretinoin combined 0.05

349 Total change (%)

P Mild/mod Percent change: -26 (52.) 14

Í Ibuprofen + placebo 0.05

2-factor ANOVA

Mid (8)

349 Total change (%)

P Mild/mod Percent change: -16 (44.) 16

Í Placebo NS

2-factor ANOVA

Mid (8)

349 Total change (%)

P Mild/mod Percent change: -26 (36.) 15

Í Tetracycline + placebo 0.05

2-factor ANOVA

Mid (8)

349 Total lesion (count)

P Mild/mod Change*: -8 14

Í Short (4) Ibuprofen + placebo

349 Total lesion (count)

P Mild/mod Change*: -1 16

Í Short (4) Placebo

349 Total lesion (count)

P Mild/mod Change*: -3 15

Í Short (4) Tetracycline + placebo

 TRIAL: refer to the presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., refer to our assessment of entry severity of 

study patients. "P" refers to parallel study, "S," to split face design. TREATMENT: "Percent change" indicates an outcome derived from individual final and baseline 

measures; "Percent change*" indicates that we calculated a group-based percentage change; "Change" indicates raw difference from baseline; "Change*" indicates 

calculated change; "Measure" indicates an outcome measure with no baseline comparison. SD indicates standard deviation, SS, sample size (with * means calcuted as total 

sample size divided by number of arms), and WITHIN P, P-value with respect to baseline."M" means no P-value available. BETWEENP-VALUE: a comparison between 

Treatment and another treatment. "Sig" indicates authors' statement regarding statistical significance, without quantitation.

Table MULTI.2 Page 10 of 10

ÈÍ